Sandipan Roy Chowdhury
Overview
Explore the profile of Sandipan Roy Chowdhury including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
187
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang L, Lin H, Yang B, Jiang X, Chen J, Roy Chowdhury S, et al.
J Am Chem Soc
. 2024 Jul;
146(32):22396-22404.
PMID: 39079063
Although many redox signaling molecules are present at low concentrations, typically ranging from micromolar to submicromolar levels, they often play essential roles in a wide range of biological pathways and...
2.
Lu D, Chen J, Qin L, Bijou I, Yi P, Li F, et al.
J Med Chem
. 2024 Mar;
67(7):5333-5350.
PMID: 38551814
Steroid receptor coactivator 3 (SRC-3) is a critical mediator of many intracellular signaling pathways that are crucial for cancer proliferation and metastasis. In this study, we performed structure-activity relationship exploration...
3.
Roy Chowdhury S, Chuong P, Mgbemena V, Statsyuk A
bioRxiv
. 2024 Jan;
PMID: 38260247
A series of Chk1 degraders were designed and synthesized. The degraders were developed through the conjugation of a promiscuous kinase binder and thalidomide. One of the degraders PROTAC-2 was able...
4.
Daskalova S, Dedkova L, Maini R, Talukder P, Bai X, Roy Chowdhury S, et al.
J Am Chem Soc
. 2023 Oct;
145(43):23600-23608.
PMID: 37871253
The introduction of noncanonical amino acids into proteins and peptides has been of great interest for many years and has facilitated the detailed study of peptide/protein structure and mechanism. In...
5.
Paudel R, Lu D, Roy Chowdhury S, Monroy E, Wang J
Biochemistry
. 2022 Sep;
62(3):564-579.
PMID: 36130224
In the scope of targeted protein degradation (TPD), proteolysis-targeting chimeras (PROTACs), leveraging the ubiquitin-proteasome system, have been extensively studied. However, they are limited to the degradation of soluble and membrane...
6.
Shahid T, Mandal S, Biswal S, De A, Mukherjee M, Roy Chowdhury S, et al.
Radiat Oncol
. 2022 Aug;
17(1):145.
PMID: 35986327
Aim: This study aims to report preclinical validation, and the first clinical treatment of total bone marrow irradiation (TMI) and total bone marrow and lymph nodal irradiation (TMLI) using Volumetric...
7.
Roy Chowdhury S, Kennedy S, Zhu K, Mishra R, Chuong P, Nguyen A, et al.
Bioorg Med Chem Lett
. 2018 Nov;
29(1):36-39.
PMID: 30455147
Here we present a virtual docking screen of 1648 commercially available covalent fragments, and identified covalent inhibitors of cysteine protease cathepsin L. These inhibitors did not inhibit closely related protease...
8.
Khdour O, Bandyopadhyay I, Visavadiya N, Roy Chowdhury S, Hecht S
Medchemcomm
. 2018 Oct;
9(9):1491-1501.
PMID: 30288223
Friedreich's ataxia (FRDA) is a progressive neurodegenerative disease that is linked to transcriptional repression of the nuclear FXN gene encoding the essential mitochondrial protein frataxin (FXN). Compounds that increase frataxin...
9.
Bandyopadhyay I, Roy Chowdhury S, Visavadiya N, Hecht S, Khdour O
Data Brief
. 2018 Sep;
20:1105-1114.
PMID: 30225325
As part of an ongoing program to develop potential therapeutic agents for the treatment of the neurodegenerative disease Friedreich׳s ataxia (FRDA), we have prepared a number of lipophilic methylene blue...
10.
Khdour O, Bandyopadhyay I, Roy Chowdhury S, Visavadiya N, Hecht S
Bioorg Med Chem
. 2018 May;
26(12):3359-3369.
PMID: 29773347
Friedreich's ataxia (FRDA) is an autosomal recessive neurodegenerative disorder resulting from reduced expression of the protein frataxin (FXN). Although its function is not fully understood, frataxin appears to help assemble...